Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Hyperlipidaemias.
|
|
Dosage/Direction for Use
Adult: PO 100 mg/day.
|
|
Administration
May be taken with or without food.
|
|
Contraindications
Severe hepatic and renal (CrCl <30 mL/min) impairment. Pregnancy and lactation. Concurrent use w/ other fibrates.
|
|
Special Precautions
Patient w/ hypoalbuminaemia, nephrotic syndrome, hypothyroidism, alcohol abuse, history of hereditary muscular disorder, previous toxicity w/ other fibrates. Mild to moderate hepatic and renal impairment. Patient Counselling This drug may cause dizziness, somnolence, and fatigue, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for renal function. Perform periodic LFT every 3 mth for the 1st yr of treatment. Monitor for serum creatine phosphokinase (CPK) levels of patients reporting unexplained muscle pain, tenderness, or weakness.
|
|
Adverse Reactions
Urticaria, rashes, pruritus, eczema; elevated CPK levels, myalgia, myositis; headache, vertigo; nausea, vomiting, anorexia, diarrhoea, dyspepsia, abdominal pain; thrombocytopenia. Rarely, photosensitivity, alopecia, rhabdomyolysis, dizziness, somnolence, impotence, cholestasis, cytolysis, pneumonitis, pulmonary fibrosis, fatigue, leukocytopenia, pancreatitis, peripheral neuropathy.
|
|
Drug Interactions
Increased risk of muscle effects esp rhabdomyolysis w/ HMG-CoA reductase inhibitors. Reduced absorption w/ cholestyramine and colestipol. May increase the effects of phenytoin, tolbutamide and other sulphonylurea derivatives, and coumarin-like anticoagulants. May potentiate the effect of warfarin.
|
|
CIMS Class
|
|
ATC Classification
C10AB08 - ciprofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
|
